Core Viewpoint - The stock price of Yidu Tech (02158) surged over 9% after the approval of a key laboratory focused on intelligent diagnosis and treatment systems, marking a significant milestone in the company's specialization in intelligent diagnosis [1] Company Summary - Yidu Tech's stock rose by 7.45% to HKD 6.35, with a trading volume of HKD 149 million [1] - The company is a core partner in the newly approved "Multimodal Intelligent Diagnosis and Treatment System Research and Application Key Laboratory" led by Peking University First Hospital, focusing on intelligent diagnosis for metabolic syndrome [1] - Yidu Tech will integrate its large model technology capabilities into the laboratory's research chain, providing a solid foundation for the implementation of intelligent diagnosis [1] Industry Summary - The global AI healthcare market is entering a trillion-dollar growth phase, with an estimated market size of USD 26.65 billion (approximately RMB 186.1 billion) in 2024, projected to soar to USD 505.59 billion (approximately RMB 3.5 trillion) by 2033, reflecting a compound annual growth rate of 38.8% [1] - Dongguan Securities indicates that the active involvement of domestic tech giants in the AI healthcare sector is expected to accelerate the informatization and accessibility of healthcare in China, making healthcare a significant breakthrough area for AI applications [1]

Group 1 - The core viewpoint of the article highlights the strong stock performance of Yidu Tech (02158), which saw a price increase of over 9% after the opening, closing at 6.35 HKD with a trading volume of 149 million HKD [1] - Yidu Tech participated in the establishment of a key laboratory focused on the development and application of a multimodal intelligent diagnosis and treatment system, led by Peking University First Hospital, marking a significant milestone in the company's commitment to specialized intelligent diagnosis [1] - The laboratory will concentrate on intelligent diagnosis for metabolic syndrome related to heart and kidney diseases, integrating Yidu Tech's large model technology capabilities into the research chain [1] Group 2 - The global AI healthcare market is entering a trillion-dollar growth phase, with a projected market size of approximately 26.65 billion USD (about 186.1 billion RMB) in 2024, expected to surge to around 505.59 billion USD (about 3.5 trillion RMB) by 2033, reflecting a compound annual growth rate of 38.8% [1] - Dongguan Securities indicates that the active involvement of domestic tech giants in the AI healthcare sector is likely to accelerate the informatization and accessibility of healthcare in China, positioning healthcare as a crucial breakthrough area for AI applications [1]

Core Viewpoint - Yidu Tech (02158) saw a significant stock increase of over 6%, currently trading at 5.94 HKD with a transaction volume of 74.37 million HKD, following the approval of a key laboratory focused on intelligent diagnosis and treatment systems for metabolic syndrome [1] Group 1 - The "Multimodal Intelligent Diagnosis and Treatment System Research and Application Key Laboratory" has been successfully approved, led by Peking University First Hospital with Yidu Tech as a core partner [1] - The laboratory will focus on intelligent diagnosis and treatment for heart-kidney metabolic syndrome, marking a significant milestone in Yidu Tech's commitment to specialized intelligent diagnosis [1] - Yidu Tech will integrate its large model technology capabilities into the laboratory's research chain, providing a solid foundation for the implementation of intelligent diagnosis [1] Group 2 - The development of medical artificial intelligence has entered a phase of value verification through practical application [1] - The establishment of the laboratory exemplifies a collaborative innovation model that integrates industry, academia, research, and medicine [1] - Yidu Tech has partnered with several renowned hospitals in China to establish joint laboratories, supporting research from data governance to model development and system construction [1]

Core Viewpoint - The recent approval of the "Multimodal Intelligent Diagnosis and Treatment System Research and Application Key Laboratory" led by Peking University First Hospital, with the participation of Yidu Tech (02158), marks a significant milestone in the company's focus on specialized intelligent diagnosis and treatment [1] Group 1: Company Developments - Yidu Tech's stock rose over 6% and was trading at 5.94 HKD with a transaction volume of 74.37 million HKD [1] - The laboratory will focus on intelligent diagnosis and treatment for metabolic syndrome related to heart and kidney diseases, showcasing Yidu Tech's commitment to advancing specialized healthcare solutions [1] - As a core co-builder of the laboratory, Yidu Tech will integrate its large model technology capabilities into the research chain, providing a solid foundation for the implementation of intelligent diagnosis [1] Group 2: Industry Trends - The development of medical artificial intelligence has entered a phase of value verification through practical applications, indicating a shift towards real-world implementation [1] - The establishment of the laboratory exemplifies a collaborative innovation model that integrates industry, academia, and healthcare, highlighting the importance of partnerships in advancing medical technology [1] - Yidu Tech has collaborated with several well-known hospitals in China to build joint laboratories, demonstrating its comprehensive technical capabilities from data governance to model development and system construction [1]

Core Insights - The core focus of the news is on the advancements and recognition of Yidu Technology in the AI healthcare sector, highlighting its participation in international collaborations and contributions to sustainable health development. Group 1: International Collaboration and Recognition - Yidu Technology has joined the Shanghai Cooperation Organization's Economic Platform Health Sustainable Development Working Committee, marking a significant step in international health cooperation [1][6] - CEO Xu Jiming has been elected as the first director of the committee, reflecting the company's technical strength and contributions to the industry [6] - Yidu Technology was appointed as a vice-chair unit of the China Internet Association's Smart Healthcare Working Committee, aiming to promote the development of smart healthcare [9] Group 2: Academic and Research Initiatives - Founder and Chairman Gong Rujing has been appointed as a member of the Advisory Committee of the Hong Kong City University Digital Medicine Research Institute, recognizing her efforts in integrating AI and big data in healthcare [2] - Yidu Technology has established a practice base with Tsinghua University's School of Public Health, resulting in 11 research outputs and advancements in key technologies [17] Group 3: Innovation and Industry Development - At the 2025 China Social Medical New Ecology Conference, CEO Xu Jiming emphasized the need for non-public healthcare to transition from resource competition to value and experience competition, proposing three key areas for enhancing core competitiveness [15] - Yidu Technology shared its experiences in AI-driven clinical trials at the AI + Drug Development Salon, focusing on improving clinical trial efficiency and data quality [16] - The company participated in the China and International Development Forum, discussing innovative digital health cooperation models [11]

Core Viewpoint - The Hong Kong stock market has shown significant strength in early 2026, particularly in the AI healthcare sector, with companies like Yidu Tech experiencing notable stock price increases due to positive market expectations and supportive policies [1][2]. Group 1: Company Performance - Yidu Tech achieved a three-day stock price increase from January 2 to January 6, 2026, with a closing price of 5.66 HKD on January 6, reflecting a cumulative rise of over 8% [1]. - The company has been recognized as one of the first partners in the Henan Province National Artificial Intelligence Application Pilot Base (medical field), further solidifying its core advantages in AI healthcare technology [1]. Group 2: Industry Trends - The AI healthcare sector is experiencing strong overall performance driven by favorable policies, including two recent initiatives from Beijing aimed at promoting AI applications in healthcare from 2026 to 2027 [1]. - The "Action Plan" released by Beijing outlines a vision for widespread application of AI technology across the entire healthcare process by 2027, enhancing the quality of medical services for the public [1]. - Institutions are optimistic about the growth potential of the AI healthcare industry, anticipating that the synergy between policy support and clinical demand will accelerate the implementation of AI healthcare technologies [2].

呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 2,500,000,000 | | USD | | 0.00002 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有 ...

Yidu Tech Inc. 醫渡科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號：2158) N O T I F I C AT I O N L E T T E R 通 知 信 函 30 December 2025 Dear Non-registered holders(Note 1) Yidu Tech Inc. (the "Company") – Notice of Publication of 2026 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong ...

Yidu Tech Inc. 醫渡科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號：2158) N O T I F I C AT I O N L E T T E R 通 知 信 函 30 December 2025 Dear Registered Shareholders, Yidu Tech Inc. (the "Company") – Notice of Publication of 2026 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong Limite ...

（於開曼群島註冊成立的有限公司） (incorporated in the Cayman Islands with limited liability) Stock code 股份代號: 2158 2025/26 中期報告 Interim Report Yidu Te ch In c. 醫渡科技有限公 司 Interim Report 2025/26 中期報告 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 5 | | 業務回顧 | 6 | | 管理層討論及分析 | 14 | | 企業管治及其他資料 | 19 | | 中期財務資料審閱報告 | 33 | | 中期簡明合併綜合收益表 | 35 | | 中期簡明合併資產負債表 | 37 | | 中期簡明合併權益變動表 | 39 | | 中期簡明合併現金流量表 | 40 | | 中期簡明合併財務資料附註 | 41 | | 釋義 | 77 | 公司資料 執行董事 宮盈盈女士 （董事長） 徐濟銘先生 （首席執行官） 封曉瑛女士 謝麗女士 非執行董事 曾鳴先生 獨立非執行董事 馬維英博士 潘蓉容女士 張林琦教授 審核委員會 潘蓉容女士 （主席 ...